There appears to be controversy regarding differing patient and physician perceptions of adverse effects (AEs) in the treatment of Dupuytren disease with collagenase clostridium histolyticum (CCH). The aim of this study was to compare the number, type, and severity of AEs perceived and reported by patients and by their physician
To assess AEs following CCH injection in a standardized way, patients were given a list of predefined complications and asked to rate their severity on a 4-point Likert scale ranging from 1 (serious) to 4 (insignificant).
Eighty-five patients were included. Patients reported fewer AEs than their physician (mean, 1.48 vs 2.18). There was no agreement between physician- and patient-reported AEs except for skin lacerations, which showed fair agreement (κ = 0.257).
Patients and physicians differ in their evaluation of AEs due to CCH treatment in Dupuytren disease. A fair level of agreement was observed for skin lacerations.
Greater consensus is needed when defining AEs associated with CCH in the treatment of Dupuytren disease.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Hand Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Adverse effects of collagenase in the treatment of Dupuytren disease: a systematic review.BioDrugs. 2017; 31: 105-115
- Efficacy and Safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures.J Hand Surg Am. 2014; 39: 57-64
- The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study.J Hand Surg Am. 2015; 40: 1963-1971
- Collagenase clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes.J Hand Surg Eur Vol. 2015; 40: 124-132
- Injectable collagenase clostridium histolyticum for Dupuytren’s contracture.N Engl J Med. 2009; 361: 968-979
- Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease.J Hand Surg Am. 2010; 35: 2027-2038.e1
- Adverse effects associated with collagenase clostridium histolyticum in Dupuytren disease: a prospective study.Orthop Traumatol Surg Res. 2018; 104: 901-905
- Efficacy and adverse effects of collagenase use in the treatment of Dupuytren’s disease: a meta-analysis.Bone Joint J. 2018; 100-B: 73-80
- Dupuytren’s contracture: an audit of the outcomes of surgery.J Hand Surg Br. 2006; 31: 514-521
- Outcomes of hand surgery. British Society for surgery of the hand.J Hand Surg Br. 1995; 20: 841-855
- Assessing the outcome of disorders of the hand. Is the patient evaluation measure reliable, valid, responsive and without bias?.J Bone Joint Surg Br. 2001; 83: 235-240
- The measurement of observer agreement for categorical data.Biometrics. 1977; 33: 159-174
- Complications after treating Dupuytren’s disease. A systematic literature review.Hand Surg Rehabil. 2017; 36: 322-329
- Acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (Xiapex) for Dupuytren’s contracture.BMJ Case Rep. 2014; 2014bcr2013203338
- Flexor tendon rupture after collagenase injection for Dupuytren contracture: case report.J Hand Surg Am. 2011; 36: 1323-1325
- Complications following collagenase treatment for Dupuytren contracture.Hand (N Y). 2017; 12: NP148-NP151
- Beware of the small finger and/or the proximal interphalangeal joint? skin lacerations following collagenase injection in Dupuytren contracture.Plast Reconstr Surg. 2012; 130: 202e-204e
- Phalangeal fracture during attempted dupuytrens release following clostridial collagenase injection: case report.J Orthop Case Rep. 2017; 7: 21-24
- One year follow-up after treatment with CCH for Dupuytren’s disease: a prospective view.Rev Esp Cir Ortop Traumatol. 2018; 62: 448-457
- Collagenase in Europe from the Experimental phase to practical use.in: Pajardi G. Badalamente M.A. Hurst L.C. Collagenase in Dupuytren Disease. Springer International Publishing, 2018: 39-74
- Patient satisfaction with collagenase.J Hand Surg Am. 2016; 41: 689-697
- Better patients’ treatment experiences are associated with better postoperative results in Dupuytren’s disease.J Hand Surg Eur Vol. 2018; 43: 848-854
- Enzyme injection as nonsurgical treatment of Dupuytren’s disease.J Hand Surg Am. 2000; 25: 629-636
Published online: June 17, 2022
Accepted: April 22, 2022
Received: July 15, 2021
Publication stageIn Press Corrected Proof
No benefits in any form have been received or will be received related directly or indirectly to the subject of this article.
© 2022 by the American Society for Surgery of the Hand. All rights reserved.